Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig ® ]) in the treatment of patients with primary immunodeficiencies.
Frontiers in immunology（2022）
摘要
[This corrects the article DOI: 10.3389/fimmu.2019.00040.].
更多查看译文
关键词
SCIG,antibodies,immunoglobulins,infections,infusion site reactions,primary immunodeficiencies
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要